Gastric biopsies represent one of the most frequent specimens that the pathologist faces in routine activity. In the last decade or so, the landscape of gastric pathology has been changing with a significant and constant decline of H. pylori-related pathologies in Western countries coupled with the expansion of iatrogenic lesions due to the use...
-
2020 (v1)PublicationUploaded on: April 14, 2023
-
2022 (v1)Publication
Gastric adenocarcinoma has recently been classified into several subtypes on the basis of molecular profiling, which has been successfully reproduced by immunohistochemistry (IHC) and in situ hybridization (ISH). A series of 73 gastroesophageal dysplastic lesions (37 gastric dysplasia and 36 Barrett dysplasia; 44 low-grade dysplasia and 29...
Uploaded on: February 4, 2024 -
2021 (v1)Publication
: The 2019 WHO classification of digestive system tumors significantly reformed the classificatory definition of serrated lesions of the colorectal mucosa and added new essential diagnostic criteria for both conventional adenomas and hereditary gastrointestinal polyposis syndromes. Histopathological examination of colorectal adenocarcinoma...
Uploaded on: March 27, 2023 -
2021 (v1)Publication
: Gastric carcinoma (GC) represents one of the most common and most lethal malignancies worldwide. The histopathological characterization of GC precursor lesions has provided great knowledge about gastric carcinogenesis, with the consequent introduction of effective strategies of primary and secondary prevention. In recent years, a large amount...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
No description
Uploaded on: February 11, 2024 -
2022 (v1)Publication
Despite the important advances in research on neuroendocrine neoplasms of the gastro-entero-pancreatic tract (GEP-NENs), their precursor lesions are much less well known.
Uploaded on: February 14, 2024 -
2024 (v1)Publication
: Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months). Areas covered: The current study includes extensive...
Uploaded on: July 3, 2024